Patients sue Gilead, telling drug Inc. intentionally delayed safer HIV virus medicine
The lawsuits tell that Gilead knew while Viread was confirmed in 2001 that it had to be given in high doses to be efficient, that meant it can damage the kidneys & bones. Yet the Inc. failed to adequately disclose those Risks in the medicine's label, the lawsuits tell.Patients sue Gilead over alleged delays in emerging safer HIV virus therapy
referring to Patients sue Gilead over alleged delays in emerging safer HIV virus medicationTwo California men filed a grievance versus drugmaker Gilead Sciences probably eight, claiming they were harmed because the pharmaceutical Inc. intentionally delayed the Growth of a safer version of tenofovir — its lead HIV virus therapy, reports the Los Angeles Times. The grievance alleges Gilead executives knew the Inc.'s scholars developed a less-toxic form of tenofovir as early as 2000. The HIV virus therapy poses dangers to patients' kidneys & bones. The grievance appeals HIV virus patients suffered from as many as ten years of "extra accumulated kidney & bone toxicity" as the Inc. saved the safer version on a shelf in its laboratory. The 2 men filed a parallel status which seeks class action status for patients who took the therapy from Oct. 26, 2001, until the present.collected by :Lucy William